Biallelic modifications in PALB2, also known as FANCN, led to a distinct type of Fanconi anemia, while monoallelic PALB2 variants are linked to breast cancer and ovarian cancer with a 41–60% and 3–5% absolute risk, respectively [41,42]. Here, PALB2 is linked to breast carcinoma.